Period,symbol,NAV,sharesOutstanding,researchDevelopment,effectOfAccountingCharges,incomeBeforeTax,minorityInterest,netIncome,sellingGeneralAdministrative,grossProfit,ebit,operatingIncome,otherOperatingExpenses,interestExpense,extraordinaryItems,nonRecurring,otherItems,incomeTaxExpense,totalRevenue,totalOperatingExpenses,costOfRevenue,totalOtherIncomeExpenseNet,discontinuedOperations,netIncomeFromContinuingOps,netIncomeApplicableToCommonShares,totalLiab,totalStockholderEquity,totalAssets,commonStock,otherCurrentAssets,retainedEarnings,otherLiab,treasuryStock,cash,totalCurrentLiabilities,otherStockholderEquity,propertyPlantEquipment,totalCurrentAssets,netReceivables,longTermDebt,inventory,accountsPayable,otherCurrentLiab,shortTermInvestments,changeToLiabilities,totalCashflowsFromInvestingActivities,netBorrowings,totalCashFromFinancingActivities,issuanceOfStock,changeInCash,effectOfExchangeRate,totalCashFromOperatingActivities,depreciation,otherCashflowsFromInvestingActivities,otherCashflowsFromFinancingActivities,changeToNetincome,capitalExpenditures,investments,changeToOperatingActivities,changeToInventory,changeToAccountReceivables,WC,language,region,quoteType,triggerable,quoteSourceName,dividendDate,regularMarketChangePercent,regularMarketDayRange,ask,bid,regularMarketPreviousClose,bidSize,askSize,messageBoardId,fullExchangeName,longName,financialCurrency,averageDailyVolume3Month,averageDailyVolume10Day,fiftyTwoWeekLowChange,fiftyTwoWeekLowChangePercent,fiftyTwoWeekRange,fiftyTwoWeekHighChange,fiftyTwoWeekHighChangePercent,fiftyTwoWeekLow,fiftyTwoWeekHigh,currency,marketState,regularMarketPrice,regularMarketTime,regularMarketChange,regularMarketOpen,regularMarketDayHigh,regularMarketDayLow,regularMarketVolume,market,priceHint,exchangeDataDelayedBy,twoHundredDayAverageChangePercent,shortName,exchange,epsTrailingTwelveMonths,bookValue,fiftyDayAverage,fiftyDayAverageChange,fiftyDayAverageChangePercent,twoHundredDayAverage,twoHundredDayAverageChange,marketCap,priceToBook,sourceInterval,exchangeTimezoneName,exchangeTimezoneShortName,gmtOffSetMilliseconds,esgPopulated,tradeable,Beta (5Y Monthly),52-Week Change 3,S&P500 52-Week Change 3,52 Week High 3,52 Week Low 3,50-Day Moving Average 3,200-Day Moving Average 3,Avg Vol (3 month) 3,Avg Vol (10 day) 3,Shares Outstanding 5,Implied Shares Outstanding 6,Float,% Held by Insiders 1,% Held by Institutions 1,"Shares Short (Jul 29, 2021) 4","Short Ratio (Jul 29, 2021) 4","Short % of Float (Jul 29, 2021) 4","Short % of Shares Outstanding (Jul 29, 2021) 4","Shares Short (prior month Jun 29, 2021) 4",Forward Annual Dividend Rate 4,Forward Annual Dividend Yield 4,Trailing Annual Dividend Rate 3,Trailing Annual Dividend Yield 3,5 Year Average Dividend Yield 4,Payout Ratio 4,Dividend Date 3,Ex-Dividend Date 4,Last Split Factor 2,Last Split Date 3,Fiscal Year Ends,Most Recent Quarter (mrq),Profit Margin,Operating Margin (ttm),Return on Assets (ttm),Return on Equity (ttm),Revenue (ttm),Revenue Per Share (ttm),Quarterly Revenue Growth (yoy),Gross Profit (ttm),EBITDA,Net Income Avi to Common (ttm),Diluted EPS (ttm),Quarterly Earnings Growth (yoy),Total Cash (mrq),Total Cash Per Share (mrq),Total Debt (mrq),Total Debt/Equity (mrq),Current Ratio (mrq),Book Value Per Share (mrq),Operating Cash Flow (ttm),Levered Free Cash Flow (ttm),index,zip,sector,longBusinessSummary,city,phone,state,compensationAsOfEpochDate,country,website,maxAge,address1,fax,industry
t0,GENE,17480659.0,15027900,530846,,-1737548,,-1737548,1608426,-83295,-1843836,-1843836,-378730,-3712,,,,0,8218,1852054,91513,106288,,-1737548,-1737548,1362645.0,17480659.0,18843304.0,147068272.0,230447.0,-139522132.0,4812.0,9934519.0,16435109.0,1241399.0,9934519.0,755198.0,18088106.0,1308481.0,46741.0,114069.0,502750.0,,,0.0,-260091.0,-57397.0,3237483.0,3688600.0,1110475.0,10937.0,-1877855.0,104651.0,15500.0,-393720.0,-244958.0,-278187.0,,,,,16846707.0,en-US,US,EQUITY,True,Delayed Quote,1565827200,-0.29498497,3.37 - 3.47,3.45,3.39,3.39,8,8,finmb_2035105,NasdaqCM,Genetic Technologies Limited,AUD,655225,136116,0.61000013,0.22021666,2.77 - 8.18,-4.8,-0.58679706,2.77,8.18,USD,POST,3.38,1630526402,-0.00999999,3.4,3.47,3.37,164324,us_market,4,0,-0.15231253,Genetic Technologies Ltd,NCM,-0.6,1.2,3.388611,-0.008610964,-0.0025411486,3.9873188,-0.60731864,58094088,2.8166666,15,America/New_York,EDT,-14400000,False,False,0.9,,,8.18,2.77,3.3886,3.9873,655.23k,136.12k,15.03M,,12.08M,1.17%,2.37%,1.06M,1.93,,7.04%,909.45k,,,,,,0.00%,"Aug 14, 2019",,1:4,"Aug 14, 2019","Jun 29, 2020","Dec 30, 2020",0.00%,"-32,763.92%",-45.42%,-68.10%,25.71k,0.00,"2,704.80%",-241.65k,-8.3M,-6.93M,-0.6000,,16.44M,1.19,367k,2.10,14.57,1.20,-6.6M,-6.12M,Value,3065,Healthcare,"Genetic Technologies Limited, a molecular diagnostics company, provides predictive testing and assessment tools to help physicians manage women's health in Australia and the United States. The company's lead product is the BREVAGenplus, a clinically validated risk assessment test for non-hereditary breast cancer. It also markets BREVAGenplus to healthcare professionals in breast health care and imaging centers, as well as to obstetricians/gynecologists and breast cancer risk assessment specialists, such as breast surgeons. In addition, the company engages in the development of various cancer risk assessment tests under the GeneType for Colorectal Cancer and GeneType for Breast Cancer name. Further, it offers genetic testing services, including medical, animal, forensic, and plant testing. The company has research and collaboration agreements with the University of Melbourne, Translational Genomics Research Institute, Memorial Sloan Kettering New York Cambridge University, the Ohio State University, and Shivom. Genetic Technologies Limited was founded in 1989 and is headquartered in Fitzroy, Australia.",Fitzroy,61 3 8412 7000,VIC,1609372800,Australia,http://www.gtglabs.com,86400,60-66 Hanover Street,61 3 8412 7040,Diagnostics & Research
t-1,GENE,17480659.0,15027900,530846,,-1737548,,-1737548,1608426,-83295,-1843836,-1843836,-378730,-3712,,,,0,8218,1852054,91513,106288,,-1737548,-1737548,1362645.0,17480659.0,18843304.0,147068272.0,230447.0,-139522132.0,4812.0,9934519.0,16435109.0,1241399.0,9934519.0,755198.0,18088106.0,1308481.0,46741.0,114069.0,502750.0,,,0.0,-260091.0,-57397.0,3237483.0,3688600.0,1110475.0,10937.0,-1877855.0,104651.0,15500.0,-393720.0,-244958.0,-278187.0,,,,,16846707.0,en-US,US,EQUITY,True,Delayed Quote,1565827200,-0.29498497,3.37 - 3.47,3.45,3.39,3.39,8,8,finmb_2035105,NasdaqCM,Genetic Technologies Limited,AUD,655225,136116,0.61000013,0.22021666,2.77 - 8.18,-4.8,-0.58679706,2.77,8.18,USD,POST,3.38,1630526402,-0.00999999,3.4,3.47,3.37,164324,us_market,4,0,-0.15231253,Genetic Technologies Ltd,NCM,-0.6,1.2,3.388611,-0.008610964,-0.0025411486,3.9873188,-0.60731864,58094088,2.8166666,15,America/New_York,EDT,-14400000,False,False,0.9,,,8.18,2.77,3.3886,3.9873,655.23k,136.12k,15.03M,,12.08M,1.17%,2.37%,1.06M,1.93,,7.04%,909.45k,,,,,,0.00%,"Aug 14, 2019",,1:4,"Aug 14, 2019","Jun 29, 2020","Dec 30, 2020",0.00%,"-32,763.92%",-45.42%,-68.10%,25.71k,0.00,"2,704.80%",-241.65k,-8.3M,-6.93M,-0.6000,,16.44M,1.19,367k,2.10,14.57,1.20,-6.6M,-6.12M,Value,3065,Healthcare,"Genetic Technologies Limited, a molecular diagnostics company, provides predictive testing and assessment tools to help physicians manage women's health in Australia and the United States. The company's lead product is the BREVAGenplus, a clinically validated risk assessment test for non-hereditary breast cancer. It also markets BREVAGenplus to healthcare professionals in breast health care and imaging centers, as well as to obstetricians/gynecologists and breast cancer risk assessment specialists, such as breast surgeons. In addition, the company engages in the development of various cancer risk assessment tests under the GeneType for Colorectal Cancer and GeneType for Breast Cancer name. Further, it offers genetic testing services, including medical, animal, forensic, and plant testing. The company has research and collaboration agreements with the University of Melbourne, Translational Genomics Research Institute, Memorial Sloan Kettering New York Cambridge University, the Ohio State University, and Shivom. Genetic Technologies Limited was founded in 1989 and is headquartered in Fitzroy, Australia.",Fitzroy,61 3 8412 7000,VIC,1609372800,Australia,http://www.gtglabs.com,86400,60-66 Hanover Street,61 3 8412 7040,Diagnostics & Research
t-2,GENE,13015370.0,15027900,674727,,-1725616,,-1725616,1317111,-23866,-2368621,-2368621,352917,-22480,,,,0,4639,2373260,28505,643005,,-1725616,-1725616,2617609.0,13015370.0,15632979.0,140111073.0,,-135851192.0,979164.0,8755489.0,14214160.0,1397572.0,8755489.0,440230.0,15192749.0,789354.0,52252.0,91390.0,350151.0,134318.0,2025.0,347827.0,-6537.0,-15966.0,7155935.0,8646856.0,5468543.0,-254431.0,-1426423.0,61369.0,-10436.0,-1474956.0,-125858.0,-17789.0,21690.0,30912.0,-29763.0,14706.0,13795177.0,en-US,US,EQUITY,True,Delayed Quote,1565827200,-0.29498497,3.37 - 3.47,3.45,3.39,3.39,8,8,finmb_2035105,NasdaqCM,Genetic Technologies Limited,AUD,655225,136116,0.61000013,0.22021666,2.77 - 8.18,-4.8,-0.58679706,2.77,8.18,USD,POST,3.38,1630526402,-0.00999999,3.4,3.47,3.37,164324,us_market,4,0,-0.15231253,Genetic Technologies Ltd,NCM,-0.6,1.2,3.388611,-0.008610964,-0.0025411486,3.9873188,-0.60731864,58094088,2.8166666,15,America/New_York,EDT,-14400000,False,False,0.9,,,8.18,2.77,3.3886,3.9873,655.23k,136.12k,15.03M,,12.08M,1.17%,2.37%,1.06M,1.93,,7.04%,909.45k,,,,,,0.00%,"Aug 14, 2019",,1:4,"Aug 14, 2019","Jun 29, 2020","Dec 30, 2020",0.00%,"-32,763.92%",-45.42%,-68.10%,25.71k,0.00,"2,704.80%",-241.65k,-8.3M,-6.93M,-0.6000,,16.44M,1.19,367k,2.10,14.57,1.20,-6.6M,-6.12M,Value,3065,Healthcare,"Genetic Technologies Limited, a molecular diagnostics company, provides predictive testing and assessment tools to help physicians manage women's health in Australia and the United States. The company's lead product is the BREVAGenplus, a clinically validated risk assessment test for non-hereditary breast cancer. It also markets BREVAGenplus to healthcare professionals in breast health care and imaging centers, as well as to obstetricians/gynecologists and breast cancer risk assessment specialists, such as breast surgeons. In addition, the company engages in the development of various cancer risk assessment tests under the GeneType for Colorectal Cancer and GeneType for Breast Cancer name. Further, it offers genetic testing services, including medical, animal, forensic, and plant testing. The company has research and collaboration agreements with the University of Melbourne, Translational Genomics Research Institute, Memorial Sloan Kettering New York Cambridge University, the Ohio State University, and Shivom. Genetic Technologies Limited was founded in 1989 and is headquartered in Fitzroy, Australia.",Fitzroy,61 3 8412 7000,VIC,1609372800,Australia,http://www.gtglabs.com,86400,60-66 Hanover Street,61 3 8412 7040,Diagnostics & Research
t-3,GENE,13015370.0,15027900,674727,,-1725616,,-1725616,1317111,-23866,-2368621,-2368621,352917,-22480,,,,0,4639,2373260,28505,643005,,-1725616,-1725616,2617609.0,13015370.0,15632979.0,140111073.0,,-135851192.0,979164.0,8755489.0,14214160.0,1397572.0,8755489.0,440230.0,15192749.0,789354.0,52252.0,91390.0,350151.0,134318.0,2025.0,347827.0,-6537.0,-15966.0,7155935.0,8646856.0,5468543.0,-254431.0,-1426423.0,61369.0,-10436.0,-1474956.0,-125858.0,-17789.0,21690.0,30912.0,-29763.0,14706.0,13795177.0,en-US,US,EQUITY,True,Delayed Quote,1565827200,-0.29498497,3.37 - 3.47,3.45,3.39,3.39,8,8,finmb_2035105,NasdaqCM,Genetic Technologies Limited,AUD,655225,136116,0.61000013,0.22021666,2.77 - 8.18,-4.8,-0.58679706,2.77,8.18,USD,POST,3.38,1630526402,-0.00999999,3.4,3.47,3.37,164324,us_market,4,0,-0.15231253,Genetic Technologies Ltd,NCM,-0.6,1.2,3.388611,-0.008610964,-0.0025411486,3.9873188,-0.60731864,58094088,2.8166666,15,America/New_York,EDT,-14400000,False,False,0.9,,,8.18,2.77,3.3886,3.9873,655.23k,136.12k,15.03M,,12.08M,1.17%,2.37%,1.06M,1.93,,7.04%,909.45k,,,,,,0.00%,"Aug 14, 2019",,1:4,"Aug 14, 2019","Jun 29, 2020","Dec 30, 2020",0.00%,"-32,763.92%",-45.42%,-68.10%,25.71k,0.00,"2,704.80%",-241.65k,-8.3M,-6.93M,-0.6000,,16.44M,1.19,367k,2.10,14.57,1.20,-6.6M,-6.12M,Value,3065,Healthcare,"Genetic Technologies Limited, a molecular diagnostics company, provides predictive testing and assessment tools to help physicians manage women's health in Australia and the United States. The company's lead product is the BREVAGenplus, a clinically validated risk assessment test for non-hereditary breast cancer. It also markets BREVAGenplus to healthcare professionals in breast health care and imaging centers, as well as to obstetricians/gynecologists and breast cancer risk assessment specialists, such as breast surgeons. In addition, the company engages in the development of various cancer risk assessment tests under the GeneType for Colorectal Cancer and GeneType for Breast Cancer name. Further, it offers genetic testing services, including medical, animal, forensic, and plant testing. The company has research and collaboration agreements with the University of Melbourne, Translational Genomics Research Institute, Memorial Sloan Kettering New York Cambridge University, the Ohio State University, and Shivom. Genetic Technologies Limited was founded in 1989 and is headquartered in Fitzroy, Australia.",Fitzroy,61 3 8412 7000,VIC,1609372800,Australia,http://www.gtglabs.com,86400,60-66 Hanover Street,61 3 8412 7040,Diagnostics & Research
